Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Some drugs used to treat inflammation may cause hair loss.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Dupilumab helped a 13-year-old regrow hair after alopecia totalis.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

JAK inhibitors offer new hope for treating severe alopecia areata.

Leflunomide successfully treated a rare skin condition in a liver transplant patient.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Baricitinib is a promising treatment for alopecia areata.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.